Bayer Pharma AG

Coronary and peripheral artery disease as risk factors for arterial thrombosis

Coronary and peripheral artery disease as risk factors for arterial thrombosis

A link between atherothrombosis and ischaemia is now well recognized. A better understanding of the underlying pathophysiological mechanisms will give new insights into the development of more-effective and safer anticoagulants for secondary prevention of acute atherothrombosis, with a therapeutic benefit for patients with coronary and/or peripheral artery disease.


Management of coronary and peripheral artery disease

Coronary artery disease and peripheral artery disease management may be complex owing to common comorbidities, which may also require treatment (e.g. diabetes, hyperlipidaemia, obesity and hypertension). Management can be improved with increased physician and patient education and use of the latest guidelines.


About coronary and peripheral artery disease

Coronary artery disease (CAD) and peripheral arterial disease (PAD) often coexist, and the latter is a marker of systemic atherosclerosis. Most patients with PAD also have concomitant CAD, and a large burden of morbidity and mortality in patients with PAD is related to myocardial infarction, ischaemic stroke and cardiovascular death. A better understanding of the underlying pathophysiological association between CAD and PAD will lead to the development of safer and more effective therapeutic options that could benefit the clinical management of patients with one or both of these diseases.